MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-21-2025
Quest Diagnostics Incorporated Revenue 2011-2026 | DGX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Quest Diagnostics Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.87 B | 9.25 B | 9.88 B | 10.8 B | 9.44 B | 7.73 B | 7.53 B | 7.71 B | 7.52 B | 7.49 B | 7.44 B | 7.15 B | 7.38 B | 7.51 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.8 B | 7.15 B | 8.33 B |
Quarterly Revenue Quest Diagnostics Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.82 B | 2.76 B | 2.65 B | 2.49 B | 2.4 B | 2.37 B | 2.3 B | 2.34 B | 2.33 B | - | 2.49 B | 2.45 B | 2.61 B | - | 2.77 B | 2.55 B | 2.72 B | 3 B | 2.79 B | 1.83 B | 1.82 B | 1.93 B | 1.96 B | 1.95 B | 1.89 B | 1.84 B | 1.89 B | 1.92 B | 1.88 B | 1.86 B | 1.86 B | 1.86 B | 1.82 B | 1.86 B | 1.88 B | 1.91 B | 1.86 B | 1.85 B | 1.88 B | 1.92 B | 1.84 B | 1.88 B | 1.9 B | 1.9 B | 1.75 B | 1.76 B | 1.79 B | 1.82 B | 1.79 B | 1.77 B | 1.82 B | 1.88 B | 1.91 B | 1.85 B | 1.91 B | 1.9 B | 1.82 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3 B | 1.75 B | 2.08 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
41 M | $ 19.02 | 0.21 % | $ 99.4 M |  Israel |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
6.81 M | $ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
BioNano Genomics
BNGO
|
30.8 M | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
Danaher Corporation
DHR
|
23.9 B | $ 228.92 | -0.76 % | $ 167 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
DexCom
DXCM
|
3.62 B | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
20.4 M | $ 11.38 | 6.36 % | $ 323 M | Israel |
 |
Exact Sciences Corporation
EXAS
|
2.76 B | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
CareDx, Inc
CDNA
|
280 M | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
IQVIA Holdings
IQV
|
15.4 B | $ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Anixa Biosciences
ANIX
|
210 K | $ 3.12 | - | $ 99.5 K | USA |
 |
Guardant Health
GH
|
739 M | $ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K | Israel |
 |
Myriad Genetics
MYGN
|
838 M | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
Illumina
ILMN
|
4.37 B | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
4.05 B | $ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
NeoGenomics
NEO
|
661 M | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
National Research Corporation
NRC
|
149 M | $ 18.77 | 0.64 % | $ 461 M | USA |
|
Biodesix
BDSX
|
71.3 M | $ 6.8 | 1.19 % | $ 882 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
13 B | $ 250.88 | -0.87 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 182.22 | -0.43 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
3.9 B | $ 676.53 | -0.85 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
1.53 B | $ 66.55 | -0.91 % | $ 4.61 B | USA |
 |
Mettler-Toledo International
MTD
|
3.87 B | $ 1 394.19 | -1.42 % | $ 29.6 B |  Schweiz |
 |
Agilent Technologies
A
|
6.32 B | $ 136.07 | -1.13 % | $ 41.4 B | USA |
 |
Organovo Holdings
ONVO
|
144 K | - | -2.3 % | $ 19.4 M | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.52 | 2.86 % | $ 5.79 M | USA |
 |
OpGen
OPGN
|
5.2 M | - | -16.95 % | $ 1.54 M | USA |
 |
OPKO Health
OPK
|
184 M | $ 1.26 | -3.08 % | $ 874 M | USA |